Anti-influenza virus agents: Synthesis and mode of action

Medicinal Research Reviews

Volumn 28, Issue 1, 2008, Pages 1-38

  Lagoja, Irene M ^a,b   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

Antiviral drugs; Influenza; Replicative cycle; Synthesis

Indexed keywords

2' FLUORO 2' DEOXYGUANOSINE; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADAMANTANE DERIVATIVE; AMANTADINE; AMANTADINE SULFATE; AMINOCAPROIC ACID; AMITIVIR; ANSABANANIN; ANTIVIRUS AGENT; BAFILOMYCIN A1; BANANIN; BMY 27709; CYANOVIRIN N; EUBANANIN; FLUTIMIDE; HEMAGGLUTININ; INOSINATE DEHYDROGENASE INHIBITOR; IODOBANANIN; LY 311912; LY 313177; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; RIMANTADINE; SIALIC ACID DERIVATIVE; SIALIDASE INHIBITOR; TETRAHYDROFURAN DERIVATIVE; THALIMONINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANAMIVIR;

BIOLOGICAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; REVIEW; RNA TRANSCRIPTION; SIDE EFFECT; URIC ACID BLOOD LEVEL; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; HUMANS; ORTHOMYXOVIRIDAE; VIRUS REPLICATION;

EID: 37249016414     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20096     Document Type: Review

References (36)

1. Roberts NA. Anti-influenza drugs and neuraminidase inhibitors. Progress Drug Res 2001;56:195-237.
2. Shigeta S. Targets of anti-influenza chemotherapy other than neuraminidase and proton pump. Antiviral Chem Chemother 2001;12:179-188.
3. Schmidt AC. Antiviral therapy for influenza. A clinical and economic comparative review. Drugs 2004; 64(18):2031-2046.
4. Monto AS. The role of antivirals in the control of influenza. Vaccine 2003;21:1796-1800.
5. De Clercq E. Highlights in the development of new antiviral agents. Mini Rev Med Chem 2002;2:163-175.
6. Meanwell NA, Krystal M. Taking aim at a moving target - Inhibitors of influenza virus part 1: Virus adsorption, entry and uncoating. Drug Discovery Today 1996;1(8):316-324.
7. Ison MG, Hayden FG. Therapeutic options for the management of influenza. Curr Opinion Pharmacol 2001;1:482-490.
8. Kandel R, Hartshorn KL. Prophylaxis and treatment of influenza virus infection. BioDrugs 2001; 15(3):303-323.
9. Colacino JM, Staschke KA, Laver WG. Approaches and strategies for the treatment of influenza virus infections. Antiviral Chem Chemother 1999;10:155-185.
10. Palese P. Influenza: Old and new threats. Nature Med 2004;10(12 Suppl):S82-S87.
11. Sauter NK, Glick GD, Crowther RL, Park SJ, Eisen MB, Skehel JJ, Knowles JR, Wiley DC. Crystallographic detection of a second ligand binding site in influenza virus hemagglutinin. Proc Natl Acad Sci USA 1992;89(1):324-328.
12. Glick GD, Toogood PL, Wiley DC, Skehel JJ, Knowles JR. Ligand recognition by influenza virus. The binding of bivalent sialosides. J Biol Chem 1991;266(35):23660-23669.
13. Hartshorn KL, White MR, Voelker DR, Coburn J, Zaner K, Crouch EC. Mechanism of binding of surfactant protein D to influenza A viruses: Importance of binding to hemagglutinin to antiviral activity. Biochem J 2000;351(2):449-458.
14. Lees WJ, Spaltenstein A, Kingery-Wood JE, Whitesides GM. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: Multivalency and steric stabilization of particulate biological systems. J Med Chem 1994;37(20):3419-3433.
15. Mammen M, Dahmann G, Whitesides GM. Effective Inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. J Med Chem 1995;38(21):4179-4790.
16. Choi S-K, Mammen M, Whitesides GM. Monomeric inhibitors of influenza neuraminidase enhance the hemagglutination inhibition activities of polyacrylamides presenting multiple C-sialoside groups. Chem Biol 1996;3(2):97-104.
17. Pritchett TJ, Paulson JC. Basis for the potent inhibition of influenza virus infection by equine and guinea pig α 2-macroglobulin. J Biol Chem 1989;264(17):9850-9858.
18. Sabesan S, Duus JO, Neira S, Domaille P, Kelm S, Paulson JC, Bock K. Cluster sialoside inhibitors for influenza virus: Synthesis, NMR, and biological studies. J Am Chem Soc 1992;114(22):8363-8375.
19. Roy R, Zanini D, Meunier SJ, Romanowska A. Solid-phase synthesis of dendritic sialoside inhibitors of influenza A virus hemagglutinin. J Chem Soc Chem Commun 1993;24:1869-1872.
20. Spevak W, Nagy JO, Charych DH, Schaefer ME, Gilbert JH, Bednarski MD. Polymerized liposomes containing C-glycosides of sialic acid: Potent inhibitors of influenza virus in vitro infectivity. J Am Chem Soc 1993;115(3):1146-1147.
21. Ogura H, Furuhata K, Ito M, Shitori Y. Studies on nucleoside analogs. Part XXVII. Studies on sialic acids. III. Synthesis of 2-O-glycosyl derivatives of N-acetyl-D-neuraminic acid. Carbohydr Res 1986;158:37-51.
22. Klenk HD, Rott R. The molecular biology of influenza virus pathogenicity. Adv Virus Res 1988;34:247-281.
23. Goto H, Kawasaki Y. A novel mechanism for acquisition of virolence by a human influenza A virus. Proc Natl Acad Sci USA 1998;95:10224-10228.
24. Steinhauer D. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999;258:1-20.
25. Tashiro M, Klenk H, Rott R. Inhibitory effect of a protease inhibitor, leupeptin, on the development of influenza pneunomia, mediaded by concomitant bacteria. J Gen Virol 1987;68:2039-2041.
26. Kido H, Beppu Y, Imamura Y, Ye C, Murakami M, Oba K, Towatari T. The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses. Biopolymers 1999;51(1):79-86.
27. Lozitsky VP, Puzis IE, Polyar RY. Resistance of mice to reinfection after ε-aminocaproic acid treatment of primary influenza virus infection. Acta Virol 1988;32:117-122.
28. Puzis LE, Lozitsky VP. Action of epsilon-aminocaproic acid on the proteolysis system during experimental influenza in mice. Acta Virol 1988;32:515-521.
29. Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R, Krystal M. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol 1997;71:4062-4070.
30. Combrink KD, Gulgeze B, Yu K-L, Pearce BC, Trehan AK, Wei J, Deshpande M, Krystal M, Torri A, Luo G, Cianci C, Danetz S, Tiley L, Meanwell NA. Salicylamide inhibitors of influenza virus fusion. Bioorg Med Chem Lett 2000;10:1649-1652.
31. Deshpande MS, Wei J, Luo G, Cianci C, Danetz S, Torri Al, Tiley L, Krystal M, Yu K-L, Huang S, Gao Q, Meanwell NA. An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methology. Bioorg Med Chem Lett 2001;11:2393-2396.
32. Yu K-L, Torri AF, Luo G, Cianci C, Grant-Young K, Danetz S, Tiley L, Krystal M, Meanwell NA. Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5- hydroxy-cyclohexylmethylamine. Bioorg Med Chem Lett 2002;12:3379-3382.
33. Plotch SJ, O'Hara B, Morin J, Palant O, LaRocque J, Bloom JD, Lang SA. Jr., DiGrandi MJ, Bradley M, Nilakantan R, Gluzman Y. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 1999;73:140-151.
34. Hoffmann LR, Kuntz ID, White JM. Structure based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: Irreversible inhibition of infectivity. J Virol 1997;71:8808-8829.
35. Ott S, Wunderli-Allenspach H. Effect of the virostatic norakin (triperiden) on influenza virus activities. Antiviral Res 1994;24(1):37-42.
36. Shibata M, Aoki H, Tsurumi T, Sugiura Y, Nishiyama Y, Suzuki S, Maeno K. Mechanism of uncoating of influenza B virus in MDCK cells: Action of chloroquine. J Gen Virol 1983;64(5):1149-1156.